The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Chance Discovery May Provide RA Diagnostic

Chance Discovery May Provide RA Diagnostic

November 1, 2009 • By Sue Pondrom

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Our discovery was serendipity,” says Antony Rosen, MD, chief of rheumatology at Johns Hopkins University in Baltimore, of the studies that led to the unexpected discovery of antipeptidylarginine deiminase-4 (anti-PAD-4) antibodies as highly specific and potential markers of disease severity in rheumatoid arthritis (RA).

You Might Also Like
  • Within Our Reach–Funded Research Finds Highly Specific Markers of RA
  • Anti-CarP May Play Special Role in RA-Associated Mortality
  • Peripheral Helper Cells May Provide Clue to RA Pathology
Explore This Issue
November 2009
Also By This Author
  • Rheumatoid Arthritis: Time Is of the Essence

Published last year in Arthritis & Rheumatism (A&R), the groundbreaking study “was novel and extremely interesting,” according to David Karp, MD, PhD, chief of the rheumatic diseases division at the University of Texas Southwestern Medical Center in Dallas, who was not involved in the study.1 “When this is confirmed with more patients, it gives us promise of a biomarker, a possible diagnostic test, and the potential for RA prognosis.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Prior to four years ago, the Hopkins research team had been working on features that unify autoantigens in the rheumatic diseases, but not specifically on RA. They knew that the noncoded amino acid citrulline is a frequent and specific target of autoantibodies in RA and that this amino acid is formed by the post-translational deimination of arginine in a reaction catalyzed by PADs. “One of the features we found that unified antigens is that they are cleaved by this molecule called granzyme B [GrB],” Dr. Rosen says. “When we found that GrB was actually cleaving PAD-4, the enzyme we were using to generate the citrulline, we knew it was an autoantigen. That was our ‘ah-ha’ moment that led to the published study.”

Funded by the Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign of the ACR Research and Education Foundation, the innovative work by Dr. Rosen and colleagues found that, although occurring less frequently than anticyclic citrullinated peptides (CCPs), anti- PAD-4 antibodies appear to be more specific than anti- CCP antibodies. Their analysis was conducted in blood samples from patients with established RA, patients with other rheumatic disease, and healthy adults. PAD-4 autoantibodies were found in 42% of RA patients and were very infrequent in controls.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When we found that GrB was actually cleaving PAD-4, the enzyme we were using to generate the citrulline, we knew it was an autoantigen. That was our ‘ah-ha’ moment that led to the published study.

—Antony Rosen, MD

The researchers determined that the anti-PAD-4 antibodies identified a subgroup of anti-CCP-positive patients that is enriched for the PAD14 susceptibility haplotype and more severe disease. Noting that a preliminary analysis shows that anti-PAD-4 antibodies occur less frequently in early disease (12%) compared with established disease, the team believed that anti-CCP antibodies precede the anti-PAD-4 immune response and that autoantibodies or T cells may participate in amplification pathways in RA. In their A&R study, the team suggested that “during conversion from the CCP-positive, asymptomatic phase of RA to the amplifying propagation phase of the disease, novel processing of the polymorphic form of PAD-4 allows generation of unique epitopes not previously tolerized, making initiation of an anti-PAD-4 immune response more likely.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Rheumatoid Arthritis Tagged With: anti-CCP antibodies, anti-PAD-4, autoantibodies, Biomarker, Clinical research, REF News, Rheumatoid arthritisIssue: November 2009

You Might Also Like:
  • Within Our Reach–Funded Research Finds Highly Specific Markers of RA
  • Anti-CarP May Play Special Role in RA-Associated Mortality
  • Peripheral Helper Cells May Provide Clue to RA Pathology
  • Periodontitis May Provide Insight into RA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.